| Dr Steven Ray Scott, DDS | |
|
1480 W Blue Starr Dr, Claremore, OK 74017-2405 | |
| (918) 342-5070 | |
| (918) 342-5073 |
| Full Name | Dr Steven Ray Scott |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 1480 W Blue Starr Dr, Claremore, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003803917 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 4133 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Ray Scott, DDS 1480 W Blue Starr Dr, Claremore, OK 74017-2405 Ph: (918) 342-5070 | Dr Steven Ray Scott, DDS 1480 W Blue Starr Dr, Claremore, OK 74017-2405 Ph: (918) 342-5070 |
News Archive
By comparing two strains of mice - one that becomes obese and diabetic on a high-fat diet and another resistant to a high-fat regimen - researchers from the Perelman School of Medicine at the University of Pennsylvania identified genome-wide changes caused by a high-fat diet.
After trying to mollify its critics in recent years by offering better health care benefits to its employees, Wal-Mart is substantially rolling back coverage for part-time workers and significantly raising premiums for many full-time staff (Greenhouse and Abelson, 10/20).
AIMM Therapeutics, a leading human therapeutic antibody company, today announced that its partner MedImmune, LLC, the global biologics unit of AstraZeneca, has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children.
Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of a case study report based on successful treatment of Progressive Multifocal Leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris' recombinant human interleukin-7 (CYT107) and CMX001, an investigational, oral broad-spectrum antiviral drug (Chimerix, Research Triangle Park, NC) in the Journal of Antimicrobial Chemotherapy.
Hebrew University of Jerusalem researchers showed that when exposed to repeated cycles of antibiotics, bacteria evolved a new adaptation by remaining dormant for the treatment period. The results show for the first time that bacteria can develop a biological timer to survive under antibiotic exposure.
› Verified 5 days ago
Robert A. Gruenberg, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 133 W Blue Starr Dr, Claremore, OK 74017 Phone: 918-342-3477 Fax: 918-341-9670 | |
Dr. Daniel Slanker, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1014 N Douglas Dr, Claremore, OK 74017 Phone: 918-342-9008 | |
Dr. Deborah Ann Philo-costello, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 101 S Moore Ave, Claremore, OK 74017 Phone: 918-342-6400 | |
Warren Lee Murray, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 1402 N Florence Ave, Claremore, OK 74017 Phone: 918-341-2004 Fax: 918-341-4012 | |
Dr. M. Karen Willhoite, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 500 E Blue Starr Dr, Claremore, OK 74017 Phone: 918-341-2788 Fax: 918-342-0065 | |
Alicia Murray, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1402 N Florence Ave, Claremore, OK 74017 Phone: 918-341-2004 |